Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.52 |
| ▸ | CCR1 | P32246 | 5/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757228 | 0.92 | ELANE (0.53) | ELANECCR1CNR2LMNACNR1 | |
| SCHEMBL5759044 | 0.92 | ELANE (0.55) | ELANECCR1CNR2CNR1 | |
| SCHEMBL5759003 | 0.92 | CNR1 (0.49) | ELANECCR1CNR2LMNAHPGD | |
| SCHEMBL5755543 | 0.91 | ELANE (0.52) | ELANECCR1CNR2CNR1 | |
| SCHEMBL5758840 | 0.91 | CNR1 (0.47) | ELANECNR2LMNACNR1 | |
| SCHEMBL5757985 | 0.91 | ELANE (0.49) | ELANECCR1CNR2LMNAHPGD | |
| SCHEMBL27624355 | 0.90 | ELANE (0.51) | ELANECCR1CNR2CNR1 | |
| SCHEMBL5757760 | 0.90 | RECQL (0.52) | ELANELMNA | |
| SCHEMBL5759228 | 0.90 | ELANE (0.53) | ELANECCR1LMNAHPGD | |
| SCHEMBL5758917 | 0.90 | ELANE (0.50) | ELANECNR2LMNAHPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CCR1 186/4885CNR2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.